Latest News

All Articles

Filter by:
Topic
Journal Club Journal Club

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

January 02, 2023

Olutasidenib, with or without azacitidine, was well tolerated and showed meaningful clinical activity in patients with IDH1-mutated acute myeloid leukaemia.

Education

Overcoming Challenges to Provide BiTE and CAR T Cell Therapy at a Community Cancer Center

December 31, 2022

Feature Story

Pharmacists talking
Education

Reaching the Melting Point: My Time Transitioning from a Solid to a Liquid Tumor Pharmacist

December 30, 2022

Reflection on Personal Impact and Growth

Imaging scan of lung cancer
Tools and Resources Drug Updates

Pharmacist Application to Practice: Adagrasib

December 22, 2022

Sam Palmatier, Pharmacy Intern and Jeff Engle, PharmD, MS, Oncology Pharmacy Manager at Fairview Cancer Clinic – Edina write about

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Mosunetuzumab

December 22, 2022

Bernard Marini, PharmD, BCOP Clinical Pharmacist Specialist – Hematology/Oncology Clinical Associate Professor University of Michigan College of Pharmacy writes about Mosunetuzumab.

Drug Updates

Pharmacist's Application to Practice: Nadofaragene
firadenovec-vncg

December 16, 2022

Kelli Rourke, PharmD Clinical Pharmacy Specialist at The Johns Hopkins Hospital writes about nadofaragene firadenovec-vncg

Pharmacist's Application to Practice: Olutasidenib

December 01, 2022

Bernard Marini, PharmD, BCOP, Clinical Pharmacist at University of Michigan College of Pharmacy writes about Olutasidenib

Drug Updates

Pharmacist’s Application to Practice:
Mirvetuximab soravtansine-gynx

November 14, 2022

Shrina Patel, PharmD, BCOP, Clinical Pharmacy Specialist at University of Texas MD Anderson Cancer Center writes about Mirvetuximab soravtansine-gynx.

Scan of human lungs
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Tremelimumab

November 10, 2022

Tremelimumab (IMJUDO, AztraZeneca Pharmaceuticals) approved November 10, 2022 for metastatic non-small cell lung cancer and approved October 24, 2022 for unresectable hepatocellular carcinoma

Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Teclistamab-cqyv

October 25, 2022

Gavyn Walsh, PD3 Oncology Pharmacy Intern and Erin Kelley, PharmD, BCOP at M Health Fairview Masonic Cancer Clinic write about teclistamab-cqyv

Late Breaking News

Adapting Investigational Drug Services During a Pandemic

October 06, 2022

Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Futibatinib

September 30, 2022

Mei Ka Fong, Pharm.D., BCOP Clinical Pharmacist Coordinator Levine Cancer Institute, Atrium Health writes about Futibatinib